BioSpace News Archive

Biotech Bay

Relievant Announces Publication of Positive Outcomes in 12-Month SMART Sham RCT

The SMART Trial is a Level 1, randomized, sham-controlled, double-blind clinical trial for chronic low back pain whose rigor, size, and clinical outcomes are unprecedented in the field of spine care.

February 9, 2018

·

4 min read

Business

Nemaura Medical Inc. Reports Third Quarter 2017 Financial Results

The Company’s comprehensive loss was $429,724 for the three months ended December 31, 2017, an improvement of $342,087 on the same quarter in 2016.

February 9, 2018

·

3 min read

Business

Organovo Announces Fiscal Third-Quarter 2018 Results; Company Updates Full-Year Fiscal 2018 Outlook

Organovo today reported financial results for the fiscal third quarter of 2018 and updated its full-year fiscal 2018 outlook.

February 9, 2018

·

14 min read

Business

Fluidigm Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Progress

Fluidigm today announced financial results for the fourth quarter and full year ended December 31, 2017.

February 9, 2018

·

20 min read

Business

BioStem Technologies Adds Chief Revenue Officer to Executive Team

BioStem Technologies announced today, the hiring of Larry Jones, as Chief Revenue Officer.

February 9, 2018

·

2 min read

Business

CRISPR Therapeutics Announces Transition of Bill Lundberg, MD

Going forward, Dr. Lundberg will serve as a Senior Advisor to the Company and has been named Head of CRISPR’s Scientific Advisory Board.

February 9, 2018

·

4 min read

Business

Accelerate Diagnostics to Host Q4 and Full-Year 2017 Earnings Call on February 15, 2018

Accelerate Diagnostics will host a conference call on Thursday, February 15, 2018 to review its fourth quarter and full-year financial results for 2017.

February 9, 2018

·

3 min read

miRagen Therapeutics Prices Public Offering of Common Stock

In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock on the same terms and conditions.

February 9, 2018

·

6 min read

Genetown

Two New Studies Demonstrate T2Candida’s Advantages over Current Diagnostic Testing

The study also demonstrates the ability of the T2Candida Panel to identify clinically important infections missed by blood culture, while dramatically shortening the time to treat an infection with targeted therapy.

February 9, 2018

·

6 min read

Pharm Country

PAVmed Announces Completion of Offer to Exercise Series W Warrants at a Temporarily Reduced Price

PAVmed today announced the completion of its previously announced offer to exercise its publicly-traded warrants (the “Series W Warrants”) at a temporarily reduced exercise price of $2.00 per share.

February 9, 2018

·

4 min read